Benjamin Misselwitz
STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease.
Woelfel S, Dütschler J, König M, Dulovic A, Graf N, Junker D, Oikonomou V, Krieger-Grübel C, Truniger S, Franke A, Eckhold A, Forsch K, Koller S, Wyss J, Krupka N, Oberholzer M, Frei N, Geissler N, Schaub P, STAR SIGN Study Investigators, Albrich W, Friedrich M, Schneiderhan-Marra N, Misselwitz B, Korte W, Bürgi J, Brand S. STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2023; 58:678-691.
12.08.2023STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease.
12.08.2023Aliment Pharmacol Ther 2023; 58:678-691
Woelfel Simon, Dütschler Joel, König Marius, Dulovic Alex, Graf Nicole, Junker Daniel, Oikonomou Vasileios, Krieger-Grübel Claudia, Truniger Samuel, Franke Annett, Eckhold Annika, Forsch Kristina, Koller Seraina, Wyss Jacqueline, Krupka Niklas, Oberholzer Melanie, Frei Nicola Fabian, Geissler Nora, Schaub Peter, STAR SIGN Study Investigators, Albrich Werner, Friedrich Matthias, Schneiderhan-Marra Nicole, Misselwitz Benjamin, Korte Wolfgang C, Bürgi Justus J, Brand Stephan
Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2.
Woelfel S, Dütschler J, König M, Graf N, Oikonomou V, Krieger-Grübel C, Truniger S, Franke A, Eckhold A, Forsch K, Wyss J, Krupka N, Albrich W, Frei N, Geissler N, Schaub P, STAR SIGN Study Investigators, Friedrich M, Misselwitz B, Korte W, Bürgi J, Brand S. Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2. Aliment Pharmacol Ther 2022; 57:103-116.
28.10.2022Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2.
28.10.2022Aliment Pharmacol Ther 2022; 57:103-116
Woelfel Simon, Dütschler Joel, König Marius, Graf Nicole, Oikonomou Vasileios, Krieger-Grübel Claudia, Truniger Samuel, Franke Annett, Eckhold Annika, Forsch Kristina, Wyss Jacqueline, Krupka Niklas, Albrich Werner, Frei Nicola Fabian, Geissler Nora, Schaub Peter, STAR SIGN Study Investigators, Friedrich Matthias, Misselwitz Benjamin, Korte Wolfgang C, Bürgi Justus J, Brand Stephan
Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland.
Perrig K, Krupka N, Jordi S, Rossel J, Biedermann L, Greuter T, Schreiner P, Vavricka S, Juillerat P, Burri E, Zimmermann D, Maillard M, Sulz M, Brand S, Rogler G, Misselwitz B. Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland. Therap Adv Gastroenterol 2022; 15:17562848221074188.
09.02.2022Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland.
09.02.2022Therap Adv Gastroenterol 2022; 15:17562848221074188
Perrig Kathrin, Krupka Niklas, Jordi Sebastian Bruno Ulrich, Rossel Jean-Benoit, Biedermann Luc, Greuter Thomas, Schreiner Philipp, Vavricka Stephan R, Juillerat Pascal, Burri Emanuel, Zimmermann Dorothee, Maillard Michel H, Sulz Michael Christian, Brand Stephan, Rogler Gerhard, Misselwitz Benjamin
Genotype-phenotype associations of polymorphisms within the gene locus of NOD-like receptor pyrin domain containing 3 in Swiss inflammatory bowel disease patients.
Yoganathan P, Rossel J, Jordi S, Franc Y, Biedermann L, Misselwitz B, Hausmann M, Rogler G, Scharl M, Frey-Wagner I, Swiss IBD Cohort Study Group. Genotype-phenotype associations of polymorphisms within the gene locus of NOD-like receptor pyrin domain containing 3 in Swiss inflammatory bowel disease patients. BMC Gastroenterol 2021; 21:310.
03.08.2021Genotype-phenotype associations of polymorphisms within the gene locus of NOD-like receptor pyrin domain containing 3 in Swiss inflammatory bowel disease patients.
03.08.2021BMC Gastroenterol 2021; 21:310
Yoganathan Priyatharsan, Rossel Jean-Benoit, Jordi Sebastian Bruno Ulrich, Franc Yannick, Biedermann Luc, Misselwitz Benjamin, Hausmann Martin, Rogler Gerhard, Scharl Michael, Frey-Wagner Isabelle, Swiss IBD Cohort Study Group
A single nucleotide polymorphism in the gene for GPR183 increases its surface expression on blood lymphocytes of patients with inflammatory bowel disease.
Ruiz F, Wyss A, Rossel J, Sulz M, Brand S, Moncsek A, Mertens J, Roth R, Clottu A, Burri E, Juillerat P, Biedermann L, Greuter T, Rogler G, Pot C, Misselwitz B, Swiss IBD Cohort Study Group. A single nucleotide polymorphism in the gene for GPR183 increases its surface expression on blood lymphocytes of patients with inflammatory bowel disease. Br J Pharmacol 2021; 178:3157-3175.
10.03.2021A single nucleotide polymorphism in the gene for GPR183 increases its surface expression on blood lymphocytes of patients with inflammatory bowel disease.
10.03.2021Br J Pharmacol 2021; 178:3157-3175
Ruiz Florian, Wyss Annika, Rossel Jean-Benoit, Sulz Michael Christian, Brand Stephan, Moncsek Anja, Mertens Joachim C, Roth René, Clottu Aurélie S, Burri Emanuel, Juillerat Pascal, Biedermann Luc, Greuter Thomas, Rogler Gerhard, Pot Caroline, Misselwitz Benjamin, Swiss IBD Cohort Study Group
[Symptoms, diagnostic and therapy of perianal disease in patients with inflammatory bowel diseases]
Misselwitz B, Rickenbacher A, Brand S. [Symptoms, diagnostic and therapy of perianal disease in patients with inflammatory bowel diseases]. Ther Umsch 2021; 78:547-558.
01.01.2021[Symptoms, diagnostic and therapy of perianal disease in patients with inflammatory bowel diseases]
01.01.2021Ther Umsch 2021; 78:547-558
Misselwitz Benjamin, Rickenbacher Andreas, Brand Stephan
Fatigue in inflammatory bowel disease and its impact on daily activities
Schreiner P, Misselwitz B, von Känel R, Rogler G, Juillerat P, Pittet V, Vavricka S, Scharl M, Greuter T, Baumann C, Valko P, Biedermann L, Rossel J, Swiss IBD Cohort Study Group. Fatigue in inflammatory bowel disease and its impact on daily activities. Aliment Pharmacol Ther 2020; 53:138-149.
07.11.2020Fatigue in inflammatory bowel disease and its impact on daily activities
07.11.2020Aliment Pharmacol Ther 2020; 53:138-149
Schreiner Philipp, Misselwitz Benjamin, von Känel Roland, Rogler Gerhard, Juillerat Pascal, Pittet Valérie, Vavricka Stephan R, Scharl Michael, Greuter Thomas, Baumann Christian R, Valko Philipp O, Biedermann Luc, Rossel Jean-Benoit, Swiss IBD Cohort Study Group
Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More
Misselwitz B, Juillerat P, Sulz M, Siegmund B, Brand S, Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More. Digestion 2020; 101 Suppl 1:69-82.
22.06.2020Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More
22.06.2020Digestion 2020; 101 Suppl 1:69-82
Misselwitz Benjamin, Juillerat Pascal, Sulz Michael, Siegmund Britta, Brand Stephan, Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology
The impact of the rs8005161 polymorphism on G protein-coupled receptor GPR65 (TDAG8) pH-associated activation in intestinal inflammation
Tcymbarevich I, Misselwitz B, de Vallière C, Rogler G, Ruiz P, Seuwen K, Scharl M, Wagner C, Kullak-Ublick G, Lang S, Cosin-Roger J, Spalinger M, Obialo N, Rossel J, Eloranta J, Swiss IBD Cohort Study Group. The impact of the rs8005161 polymorphism on G protein-coupled receptor GPR65 (TDAG8) pH-associated activation in intestinal inflammation. BMC Gastroenterol 2019; 19:2.
07.01.2019The impact of the rs8005161 polymorphism on G protein-coupled receptor GPR65 (TDAG8) pH-associated activation in intestinal inflammation
07.01.2019BMC Gastroenterol 2019; 19:2
Tcymbarevich Irina V, Misselwitz Benjamin, de Vallière Cheryl, Rogler Gerhard, Ruiz Pedro A, Seuwen Klaus, Scharl Michael, Wagner Carsten A, Kullak-Ublick Gerd A, Lang Silvia, Cosin-Roger Jesus, Spalinger Marianne, Obialo Nicole, Rossel Jean-Benoit, Eloranta Jyrki J, Swiss IBD Cohort Study Group
Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity
Kadelka C, Bernasconi E, Hoffmann M, Calmy A, Battegay M, Rauch A, Yerly S, Aubert V, Klimkait T, Böni J, Kouyos R, Günthard H, Trkola A, Cavassini M, Misselwitz B, Liechti T, Ebner H, Schanz M, Rusert P, Friedrich N, Stiegeler E, Braun D, Huber M, Scherrer A, Weber J, Uhr T, Kuster H, Swiss HIV Cohort Study. Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity. J Exp Med 2018; 215:1589-1608.
24.05.2018Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity
24.05.2018J Exp Med 2018; 215:1589-1608
Kadelka Claus, Bernasconi Enos, Hoffmann Matthias, Calmy Alexandra, Battegay Manuel, Rauch Andri, Yerly Sabine, Aubert Vincent, Klimkait Thomas, Böni Jürg, Kouyos Roger D, Günthard Huldrych F, Trkola Alexandra, Cavassini Matthias, Misselwitz Benjamin, Liechti Thomas, Ebner Hanna, Schanz Merle, Rusert Peter, Friedrich Nikolas, Stiegeler Emanuel, Braun Dominique L, Huber Michael, Scherrer Alexandra U, Weber Jacqueline, Uhr Therese, Kuster Herbert, Swiss HIV Cohort Study
Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey
Vavricka S, Biedermann L, Michetti P, Straumann A, Misselwitz B, Scharl M, Manser C, Greuter T, Zeitz J, Frei P, Borovicka J, Seibold F, Schoepfer A, Rogler G, Spasojevic M. Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey. Dig Dis 2017; 35:423-432.
09.06.2017Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey
09.06.2017Dig Dis 2017; 35:423-432
Vavricka Stephan R, Biedermann Luc, Michetti Pierre, Straumann Alex, Misselwitz Benjamin, Scharl Michael, Manser Christine, Greuter Thomas, Zeitz Jonas, Frei Pascal, Borovicka Jan, Seibold Frank, Schoepfer Alain M, Rogler Gerhard, Spasojevic Milos
Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study
Vavricka S, Misselwitz B, Scharl M, Heinrich H, Manser C, Safroneeva E, Raja Ali R, Rogler G, Schoepfer A, Greuter T, Zeitz J, Biedermann L, Juillerat P, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, Protic M, Michetti P, Straumann A, Fournier N. Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study. Inflamm Bowel Dis 2017
27.04.2017Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study
27.04.2017Inflamm Bowel Dis 2017
Vavricka Stephan R, Misselwitz Benjamin, Scharl Michael, Heinrich Henriette, Manser Christine N, Safroneeva Ekaterina, Raja Ali Raja Affendi, Rogler Gerhard, Schoepfer Alain M, Greuter Thomas, Zeitz Jonas, Biedermann Luc, Juillerat Pascal, Gubler Martin, Gantenbein Claudine, Spoerri Muriel, Froehlich Florian, Seibold Frank, Protic Marijana, Michetti Pierre, Straumann Alex, Fournier Nicolas
Risk Factors for the Development of Fistulae and Stenoses in Crohn Disease Patients in the Swiss Inflammatory Bowel Disease Cohort
Zeitz J, Rogler G, Fried M, Sulz M, Vavricka S, Scharl S, Misselwitz B, Frei P, Biedermann L, Labenz C, Fournier N, Scharl M. Risk Factors for the Development of Fistulae and Stenoses in Crohn Disease Patients in the Swiss Inflammatory Bowel Disease Cohort. Inflamm Intest Dis 2017; 1:172-181.
25.02.2017Risk Factors for the Development of Fistulae and Stenoses in Crohn Disease Patients in the Swiss Inflammatory Bowel Disease Cohort
25.02.2017Inflamm Intest Dis 2017; 1:172-181
Zeitz Jonas, Rogler Gerhard, Fried Michael, Sulz Michael, Vavricka Stephan R, Scharl Sylvie, Misselwitz Benjamin, Frei Pascal, Biedermann Luc, Labenz Christian, Fournier Nicolas, Scharl Michael
Meta-Analysis of the Effect of Bowel Preparation on Adenoma Detection: Early Adenomas Affected Stronger than Advanced Adenomas
Sulz M, Kröger A, Prakash M, Manser C, Heinrich H, Misselwitz B. Meta-Analysis of the Effect of Bowel Preparation on Adenoma Detection: Early Adenomas Affected Stronger than Advanced Adenomas. PloS one 2016; 11:e0154149.
03.06.2016Meta-Analysis of the Effect of Bowel Preparation on Adenoma Detection: Early Adenomas Affected Stronger than Advanced Adenomas
03.06.2016PloS one 2016; 11:e0154149
Sulz Michael, Kröger Arne, Prakash Meher, Manser Christine N, Heinrich Henriette, Misselwitz Benjamin